Liquidia closes $25M Series C to fund vaccine delivery tech

Liquidia Technologies has garnered the final piece of a $25 million Series C, which will fund development of a new vaccine delivery technology. The clinical research organization PPD invested $5 million in the round, which brings Liquidia's total investments in three rounds to $49.5 million.

Liquidia, which is based in Research Triangle Park, NC, uses its PRINT technology to create nanoparticles that can be used to more precisely deliver vaccine payloads, improving the safety and efficacy of the jab. The developer has a vaccine in development that it expects to get into the clinic later this year. The same particle technology used to orchestrate adjuvants, antigens, and presentation strategies in vaccines can also be used to enhance drug delivery.

"Given PPD's broad expertise in vaccine and biologic drug development, this was a compelling opportunity for both parties," said Neal Fowler, Liquidia's CEO. PPD joined Canann Partners, New Enterprise Associates, Morningside Venture Investments, Pappas Ventures and Firelake Capital in the round.

"The vaccines market is one of the fastest growing segments in the industry, and it is an area where PPD has strong laboratory and clinical development expertise," said David L. Grange, PPD's chief executive officer.

- check out Liquidia's release
- here's the story from Local Tech Wire
- and here's the report from the Triangle Business Journal

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.